Is AGC Biologics profitable?

Not currently. AGC Inc disclosed a 'significant shortfall in sales volume' for its Biopharmaceuticals CDMO business in September 2025 investor materials, and its 'AGC plus-2026' plan targets a return to Life Science segment profitability in 2026, with full ROCE recovery only expected by 2028.

Is AGC Biologics laying off workers?

Yes. In September 2025, AGC announced closure of its Boulder and Longmont, Colorado sites with 267 to 278 layoffs effective November to December 2025, following an earlier round of about 185 Longmont layoffs in 2024.

Who owns AGC Biologics?

AGC Biologics is a wholly owned subsidiary of AGC Inc, a publicly traded Japanese conglomerate (Tokyo Stock Exchange: 5201) with a market capitalization of roughly 1.34 trillion yen as of July 24, 2026.

Who is AGC Biologics' biggest competitor?

Lonza Group leads the CDMO field with over $8 billion in revenue as of 2025 Statista data, dwarfing AGC Biologics' sub-$1 billion scale; Thermo Fisher (~$7B), Catalent (~$4.4B), Samsung Biologics (~$3.3B), and WuXi Biologics (~$2.6B) are also all far larger.

Could AI replace AGC Biologics?

Unlikely for its core work. AGC Biologics' business is physical cGMP manufacturing and regulatory approvals (it cites 90+ regulatory inspections and a 10th EMA/FDA approval at Milan in July 2025); AI so far only touches back-office process-development and QA workflows, not manufacturing itself.

Is it safe to take a job at AGC Biologics?

It depends heavily on location. US sites in Boulder and Longmont, Colorado were closed with 267 to 278 layoffs finalized by December 2025, while the Yokohama, Japan site is expanding, with about 400 new jobs planned as of November 2025.

Biotech tools companies · subsidiary of AGC Inc. (Tokyo, Japan; TSE: 5201) · United States

AGC Biologics

agcbio.com ↗

Biologics CDMO subsidiary of AGC Inc., manufacturing cell, gene, and protein therapies for drugmakers.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from 2027 · Every call on the record Checkpoint: Yokohama facility targeted to reach GMP-ready status

The call

AGC Biologics keeps winning approvals and running real plants, but it is closing US sites and shrinking while larger CDMOs pull ahead in scale.

AGC Biologics makes medicines for other pharmaceutical companies, kind of like a factory that other drug makers rent. It is hard to compete because Lonza, Thermo Fisher, and Samsung are four to ten times bigger and have more money to invest, making it risky for customers to bet on a smaller player. The parent company is closing U.S. factories in Colorado and moving money to Japan, which could help it survive but also signals trouble right now; watch whether the new Japanese plant works well and whether the parent can stabilize sales by 2028 or admits it needs to shrink more.

Why

AI pressure: None apparent. Biologics manufacturing runs on regulated wet-lab processes and GMP compliance, not something an AI model replaces. Could AI do the core job? Unlikely.

Bigger players: Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher/Patheon, Catalent. Parent AGC Inc. disclosed a significant sales volume shortfall in the CDMO unit as bigger rivals absorb more biologics contracts. Could a giant copy it? Yes, easily.

What protects it. A track record of 10+ regulatory approvals and five GMP sites across the US, Europe, and Japan keep existing customer programs locked in.

What would change this call

Outcome of the Boulder/Longmont, Colorado site sale process. Shows whether AGC is shrinking US footprint faster than it can redeploy capacity.
Whether Yokohama facility reaches GMP-ready status by the 2027 target. Indicates if AGC's growth bet on Japan capacity is on schedule.
AGC Inc.'s next semiannual Life Science investor briefing. Reveals whether the CDMO segment is stabilizing or facing further restructuring.

Key numbers

AGC Group net sales ~¥2,058B FY2025 (2026-03-09)
267 to 278 layoffs from Boulder/Longmont closures (2025-09-16)
10th regulatory approval at Milan site (Autolus CAR-T) (2025-07-31)

Named risks

Colorado site sale process unresolved, layoffs and WARN Act investigation ongoing since Sept 2025. Severity: high
Parent AGC discloses Biopharma CDMO sales shortfall, profitability delayed to 2028 ROCE target. Severity: high
Yokohama $350M facility could slip past 2027 GMP-ready target. Severity: medium
Industry consolidation (Novo-Catalent $16.5B, Samsung-PolyPeptide $1.8B) squeezes subscale AGC. Severity: medium
AGC Life Science segment could be deprioritized if shortfall persists into 2026-2027 briefings. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Lonza Group	losing to	Lonza >$8B revenue vs AGC's sub-$1B scale, per 2025-11-18 Statista data
Samsung Biologics	gaining on	Reported $1.8B all-cash bid for PolyPeptide Group, expanding scale advantage
Catalent (Novo Holdings)	contesting	Novo Holdings closed $16.5B Catalent acquisition in late 2024, reshaping CDMO landscape
WuXi Biologics	losing to	WuXi ~$2.6B revenue still exceeds AGC's unconfirmed sub-$1B base, 2025-11-18
Thermo Fisher/Patheon	losing to	Thermo Fisher CDMO revenue ~$7B dwarfs AGC scale, per 2025-11-18 data

Questions people ask

Is AGC Biologics profitable?: Not currently. AGC Inc disclosed a 'significant shortfall in sales volume' for its Biopharmaceuticals CDMO business in September 2025 investor materials, and its 'AGC plus-2026' plan targets a return to Life Science segment profitability in 2026, with full ROCE recovery only expected by 2028.
Is AGC Biologics laying off workers?: Yes. In September 2025, AGC announced closure of its Boulder and Longmont, Colorado sites with 267 to 278 layoffs effective November to December 2025, following an earlier round of about 185 Longmont layoffs in 2024.
Who owns AGC Biologics?: AGC Biologics is a wholly owned subsidiary of AGC Inc, a publicly traded Japanese conglomerate (Tokyo Stock Exchange: 5201) with a market capitalization of roughly 1.34 trillion yen as of July 24, 2026.
Who is AGC Biologics' biggest competitor?: Lonza Group leads the CDMO field with over $8 billion in revenue as of 2025 Statista data, dwarfing AGC Biologics' sub-$1 billion scale; Thermo Fisher (~$7B), Catalent (~$4.4B), Samsung Biologics (~$3.3B), and WuXi Biologics (~$2.6B) are also all far larger.
Could AI replace AGC Biologics?: Unlikely for its core work. AGC Biologics' business is physical cGMP manufacturing and regulatory approvals (it cites 90+ regulatory inspections and a 10th EMA/FDA approval at Milan in July 2025); AI so far only touches back-office process-development and QA workflows, not manufacturing itself.
Is it safe to take a job at AGC Biologics?: It depends heavily on location. US sites in Boulder and Longmont, Colorado were closed with 267 to 278 layoffs finalized by December 2025, while the Yokohama, Japan site is expanding, with about 400 new jobs planned as of November 2025.

Timeline

2026-06-30Entered fill-finish partnership with Pyramid Pharma Services for US sterile fill/finish
2026-04-15Confirmed $350M Yokohama site, GMP-ready target 2027
2026-02-19Seattle site received Brazilian Anvisa GMP certification
2025-11-19Announced ~400 planned new jobs at new Yokohama facility
2025-09-29AGC disclosed 'significant shortfall in sales volume' for Biopharma CDMO
2025-09-18WARN Act investigation opened into Colorado layoffs
2025-09-16Announced closure/sale of Boulder and Longmont sites, 267-278 layoffs
2025-07-31Milan site achieved 10th regulatory approval (Autolus CAR-T therapy)
2025-04-02Launched dedicated Cell and Gene Technologies Division
2024Laid off ~185 employees at Longmont, Colorado

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation